I am driven by a passionate curiosity for the natural world and I see my life as an enduring quest for knowledge. My current work centers on bringing together cancer genomics and metabolism, to develop novel molecular targeted therapeutics. We have pioneered a novel approach to precision oncology, collateral lethality, which utilizes passenger deletions of housekeeping genes as points of metabolic vulnerabilities. Our most advanced iteration of this strategy consists of targeting tumors with ENO1 homozygous deletions (occur in GBM, HCC, CHOL) by inhibitors of the redundant paralogue, ENO2. We generate a small molecule ENO2 inhibitor, HEX with pro-drugs of HEX showing potent pre-clinical activity and good tolerance in NHP. At the same time, I see passenger deleted genes as natural experiments that can inform on key aspects of tumor biology, including immune system/tumor interactions.